Source:http://linkedlifedata.com/resource/pubmed/id/16399574
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2006-1-9
|
| pubmed:abstractText |
The study comprised 37 consecutive patients who underwent transplantation with a Campath-1H in vitro T cell-depleted granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft from an HLA-identical sibling, followed 24 hours later by an unmanipulated graft. Acute graft-versus-host disease (GVHD) was limited to grade I to II, whereas chronic graft-versus-host disease occurred in 9 patients, mostly (n = 7) with limited disease. Molecular relapses (8 chronic myeloid leukemia [CML] and 1 non-Hodgkin lymphoma) that occurred not earlier than the sixth month after transplantation were treated with donor lymphocyte infusion (DLI), which induced complete remission in all but 1 CML patient with persistent very low BCR-ABL molecular levels. With a median follow-up of 54 months (range, 29-84 months), the actuarial 5-year overall survival, disease-free survival, and transplant-related mortality are 78% (95% confidence interval [CI], 52%-88%), 78% (95% CI, 52%-86%), and 6% (95% CI, 1.5%-32%), respectively. All CML patients are alive and free of disease. The results of this prospective, nonrandomized study show that incomplete T-cell depletion in vitro with Campath-1H (in combination with DLI for molecular relapses in CML) may decrease the incidence of GVHD and transplant-related mortality with no adverse effect on disease-free survival. The described method decreases the number of T cells to an extent that severe GVHD is prevented while relapse is postponed to a time when the patient can be treated with DLI without severe side effects.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1083-8791
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
102-10
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:16399574-Adolescent,
pubmed-meshheading:16399574-Adult,
pubmed-meshheading:16399574-Antibodies, Monoclonal,
pubmed-meshheading:16399574-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16399574-Antibodies, Neoplasm,
pubmed-meshheading:16399574-Female,
pubmed-meshheading:16399574-Graft vs Host Disease,
pubmed-meshheading:16399574-Graft vs Leukemia Effect,
pubmed-meshheading:16399574-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:16399574-Histocompatibility Testing,
pubmed-meshheading:16399574-Humans,
pubmed-meshheading:16399574-Leukocyte Reduction Procedures,
pubmed-meshheading:16399574-Lymphocyte Transfusion,
pubmed-meshheading:16399574-Male,
pubmed-meshheading:16399574-Middle Aged,
pubmed-meshheading:16399574-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:16399574-Recurrence,
pubmed-meshheading:16399574-Survival Analysis,
pubmed-meshheading:16399574-T-Lymphocytes
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
|
| pubmed:affiliation |
Hematology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland. yves.chalandon@hcuge.ch
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|